SRPT · XBRL financial data

Sarepta Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SRPT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	540	702	933	1,243	1,902	2,198
Revenue from contracts with customers	456	612	844	1,145	1,788	1,864
Cost of revenue	—	—	—	—	—	26
Selling, general and administrative	318	283	451	482	558	492
Operating income (loss)	(564)	(460)	(536)	(268)	218	(700)
Interest income	3	0	16	36	31	31
Interest expense	60	64	53	22	(18)	(38)
Other income (expense)	1	(1)	(28)	33	43	(19)
Income tax expense (benefit)	1	(0)	14	16	26	11
Net income (loss)	(554)	(419)	(703)	(536)	235	(713)
Earnings per share, basic USD per share	(7.11)	(5.15)	(8.03)	(5.80)	2.47	(7.13)
Earnings per share, diluted USD per share	(7.11)	(5.15)	(8.03)	(5.80)	2.34	(7.13)
Weighted average shares, basic millions of shares	78	81	88	92	95	100
Weighted average shares, diluted millions of shares	78	81	88	92	108	100

Fiscal years (SRPT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,503	2,116	967	428	1,103	801
Short-term investments	436	0	1,023	1,248	252	138
Marketable securities	436	0	1,023	1,248	—	—
Marketable securities, non-current	—	—	—	428	—	—
Accounts receivable	101	153	215	400	602	398
Inventory	232	186	204	323	750	915
Total current assets	2,485	2,604	2,558	2,579	3,073	2,538
Property and equipment, net	190	191	180	227	340	345
Right-of-use asset	92	46	65	130	148	125
Total assets	2,985	3,148	3,128	3,265	3,963	3,350
Accounts payable	111	77	96	165	214	281
Accrued liabilities	194	272	419	315	374	360
Current portion of long-term debt	—	—	0	105	0	—
Total current liabilities	416	453	620	654	732	1,095
Lease liability, non-current	80	42	58	141	192	199
Total liabilities	2,223	2,220	2,743	2,405	2,435	2,209
Accumulated deficit	(2,848)	(3,207)	(3,910)	(4,446)	(4,211)	(4,877)
Total stockholders' equity	762	928	385	859	1,528	1,141
Total liabilities and equity	2,985	3,148	3,128	3,265	3,963	3,350
Common shares outstanding (cover page) millions of shares	79	87	88	94	97	105

Fiscal years (SRPT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(554)	(419)	(703)	(536)	235	(713)
Stock-based compensation	108	114	233	183	184	123
Depreciation and amortization	27	38	42	44	38	45
Net cash from operating activities	107	(443)	(325)	(501)	(206)	(205)
Purchases of property and equipment	82	38	31	76	137	102
Net cash from investing activities	(122)	495	(1,047)	(166)	756	70
Proceeds from issuing common stock	312	0	0	0	0	20
Share repurchases	—	—	—	0	0	25
Proceeds from long-term debt	291	0	0	—	—	—
Net cash from financing activities	682	562	233	125	125	(168)
Net change in cash	668	614	(1,140)	(542)	675	(304)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.